Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    September 2021
  1. MCCLAIN JB, Chuang A, Reid C, Moore SM, et al
    Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01114.
    >> Share

    June 2021
  2. ODITA CI, Conan A, Smith-Antony M, Battice J, et al
    Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00719.
    >> Share

  3. ITO N, Okamoto T, Sasaki M, Miyamoto S, et al
    Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00553.
    >> Share

    April 2021
  4. JENSEN KJ, Tolstrup LK, Knobel DL, Aaby P, et al
    Non-specific effects of maternal and offspring rabies vaccination on mortality and antibiotic use in a Danish pig herd: A randomized trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00399.
    >> Share

  5. SMITH TG, Fooks AR, Moore SM, Freuling CM, et al
    Negligible risk of rabies importation in dogs thirty days after demonstration of adequate serum antibody titer.
    Vaccine. 2021 Apr 4. pii: S0264-410X(21)00368.
    >> Share

    January 2021
  6. KNOBEL DL, Arega SM, Conan A
    Sex-differential non-specific effects of rabies vaccine in dogs: An extended analysis of a randomized controlled trial in a high-mortality population.
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00045.
    >> Share

  7. ALDRICH C, Leroux-Roels I, Huang KB, Bica MA, et al
    Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.
    Vaccine. 2021 Jan 21. pii: S0264-410X(20)31667.
    >> Share

  8. XU C, Lau CL, Clark J, Rafferty AC, et al
    Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00039.
    >> Share

    July 2020
  9. TROTTER C, Abela-Ridder B, Bharti O, Knopf L, et al
    Reply to 'Alternative abridged preventive regimens against rabies for children in high endemic countries'.
    Vaccine. 2020;38:5580-5581.
    >> Share

  10. SOENTJENS P, Van Damme P, Bottieau E
    'Alternative abridged preventive regimens against rabies for children in high endemic countries'.
    Vaccine. 2020;38:5578-5579.
    >> Share

    June 2020
  11. UNDURRAGA EA, Millien MF, Allel K, Etheart MD, et al
    Costs and effectiveness of alternative dog vaccination strategies to improve dog population coverage in rural and urban settings during a rabies outbreak.
    Vaccine. 2020 Jun 29. pii: S0264-410X(20)30767.
    >> Share

  12. PARIZE P, Poujol P, Morineau Le Houssine P, Goesch J, et al
    Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies.
    Vaccine. 2020 Jun 22. pii: S0264-410X(20)30823.
    >> Share

  13. ANGSUWATCHARAKON P, Ratananpinit N, Yoksan S, Saengseesom W, et al
    Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country.
    Vaccine. 2020 Jun 7. pii: S0264-410X(20)30699.
    >> Share

  14. BONWITT J, Bonaparte S, Blanton J, Gibson AD, et al
    Oral bait preferences and feasibility of oral rabies vaccination in Bangladeshi dogs.
    Vaccine. 2020 Jun 5. pii: S0264-410X(20)30692.
    >> Share

    May 2020
  15. MORGENROTH A, Jakel V, Hanke-Robinson H, Muller T, et al
    A novel electrophoretic immunoblot as antigen desorption and quantification method for alum-adjuvanted veterinary rabies vaccines.
    Vaccine. 2020 May 8. pii: S0264-410X(20)30561.
    >> Share

  16. QUIAMBAO BP, Ambas C, Diego S, Bosch Castells V, et al
    Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
    Vaccine. 2020;38:3740-3746.
    >> Share

    September 2019
  17. LUO J, Zhang Y, He H, Liu Q, et al
    Artesunate enhances the immune response of rabies vaccine as an adjuvant.
    Vaccine. 2019 Sep 30. pii: S0264-410X(19)31305.
    >> Share

    August 2019
  18. SREENIVASAN N, Li A, Shiferaw M, Tran CH, et al
    Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017-2018.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)30475.
    >> Share

  19. ZHAO R, Yu P, Shan Y, Thirumeni N, et al
    Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)31107.
    >> Share

  20. BHARTI OK, Thakur B, Rao R
    Wound-only injection of rabies immunoglobulin (RIG) saves lives and costs less than a dollar per patient by "pooling strategy".
    Vaccine. 2019 Aug 5. pii: S0264-410X(19)31008.
    >> Share

    July 2019
  21. JANEWONGWIROT P, Jantarabenjakul W, Anugulruengkitt S, Anunsittichai O, et al
    A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children.
    Vaccine. 2019 Jul 26. pii: S0264-410X(19)30953.
    >> Share

  22. WAMBURA G, Mwatondo A, Muturi M, Nasimiyu C, et al
    Rabies vaccine and immunoglobulin supply and logistics: Challenges and opportunities for rabies elimination in Kenya.
    Vaccine. 2019 Jul 17. pii: S0264-410X(19)30659.
    >> Share

  23. TRABELSI K, Ben Zakour M, Kallel H
    Purification of rabies virus produced in Vero cells grown in serum free medium.
    Vaccine. 2019 Jul 9. pii: S0264-410X(19)30849.
    >> Share

    June 2019
  24. SOBEY KG, Jamieson SE, Walpole AA, Rosatte RC, et al
    ONRAB(R) oral rabies vaccine is shed from, but does not persist in, captive mammals.
    Vaccine. 2019 Jun 24. pii: S0264-410X(19)30808.
    >> Share

  25. GUO Z, Bai L, Gong S
    Some comments on the scandal of rabies vaccine in China.
    Vaccine. 2019 Jun 13. pii: S0264-410X(19)30732.
    >> Share

  26. ROUROU S, Ben Zakkour M, Kallel H
    Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media.
    Vaccine. 2019 Jun 11. pii: S0264-410X(19)30749.
    >> Share

    May 2019
  27. FORRO B, Marton S, Kecskemeti S, Hornyak A, et al
    Vaccine-associated rabies in red fox, Hungary.
    Vaccine. 2019 May 17. pii: S0264-410X(19)30628.
    >> Share

    March 2019
  28. WENTWORTH D, Hampson K, Thumbi SM, Mwatondo A, et al
    A social justice perspective on access to human rabies vaccines.
    Vaccine. 2019 Mar 27. pii: S0264-410X(19)30150.
    >> Share

  29. TAYLOR E, Banyard AC, Bourhy H, Cliquet F, et al
    Avoiding preventable deaths: The scourge of counterfeit rabies vaccines.
    Vaccine. 2019 Mar 25. pii: S0264-410X(19)30369.
    >> Share

  30. QUIAMBAO BP, Ambas C, Diego S, Bosch Castells V, et al
    Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Vaccine. 2019 Mar 16. pii: S0264-410X(19)30335.
    >> Share

  31. CHEN T, Zhou X, Qi Y, Mi L, et al
    Feline herpesvirus vectored-rabies vaccine in cats: A dual protection.
    Vaccine. 2019 Mar 13. pii: S0264-410X(19)30310.
    >> Share

    February 2019
  32. DOENER F, Hong HS, Meyer I, Tadjalli-Mehr K, et al
    RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.
    Vaccine. 2019 Feb 21. pii: S0264-410X(19)30219.
    >> Share

  33. KESSELS J, Tarantola A, Salahuddin N, Blumberg L, et al
    Rabies post-exposure prophylaxis: A systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course.
    Vaccine. 2019 Feb 5. pii: S0264-410X(19)30105.
    >> Share

  34. TRAN CH, Afriyie DO, Pham TN, Otsu S, et al
    Rabies post-exposure prophylaxis initiation and adherence among patients in Vietnam, 2014-2016.
    Vaccine. 2019 Feb 2. pii: S0264-410X(19)30093.
    >> Share

    January 2019
    Rabies post-exposure vaccination in 2 visits within a week: A 4-site intradermal regimen.
    Vaccine. 2019 Jan 25. pii: S0264-410X(19)30073.
    >> Share

  36. RUPPRECHT CE, Kuzmin IV, Yale G, Nagarajan T, et al
    Priorities in applied research to ensure programmatic success in the global elimination of canine rabies.
    Vaccine. 2019 Jan 23. pii: S0264-410X(19)30068.
    >> Share

    December 2018
  37. RYSAVA K, Miranda ME, Zapatos R, Lapiz S, et al
    On the path to rabies elimination: The need for risk assessments to improve administration of post-exposure prophylaxis.
    Vaccine. 2018 Dec 17. pii: S0264-410X(18)31627.
    >> Share

  38. ANOTHAISINTAWEE T, Julienne Genuino A, Thavorncharoensap M, Youngkong S, et al
    Cost-effectiveness modelling studies of all preventive measures against rabies: A systematic review.
    Vaccine. 2018 Dec 13. pii: S0264-410X(18)31634.
    >> Share

  39. DENIS M, Knezevic I, Wilde H, Hemachudha T, et al
    An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route.
    Vaccine. 2018 Dec 11. pii: S0264-410X(18)31635.
    >> Share

  40. HAMPSON K, Abela-Ridder B, Bharti O, Knopf L, et al
    Modelling to inform prophylaxis regimens to prevent human rabies.
    Vaccine. 2018 Dec 7. pii: S0264-410X(18)31519.
    >> Share

  41. RATTANAVIPAPONG W, Thavorncharoensap M, Youngkong S, Genuino AJ, et al
    The impact of transmission dynamics of rabies control: Systematic review.
    Vaccine. 2018 Dec 5. pii: S0264-410X(18)31558.
    >> Share

    November 2018
  42. RAJEEV M, Edosoa G, Hanitriniaina C, Andriamandimby SF, et al
    Healthcare utilization, provisioning of post-exposure prophylaxis, and estimation of human rabies burden in Madagascar.
    Vaccine. 2018 Nov 30. pii: S0264-410X(18)31520.
    >> Share

  43. SPARROW E, Torvaldsen S, Newall AT, Wood JG, et al
    Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline.
    Vaccine. 2018 Nov 29. pii: S0264-410X(18)31503.
    >> Share

  44. TARANTOLA A, Tejiokem MC, Briggs DJ
    Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines.
    Vaccine. 2018 Nov 21. pii: S0264-410X(18)31542.
    >> Share

  45. TARANTOLA A, Ly S, Chan M, In S, et al
    Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003-2014.
    Vaccine. 2018 Nov 16. pii: S0264-410X(18)31420.
    >> Share

  46. IVES A, Dieuzy-Labaye I, Abela-Ridder B
    Global characteristics of the rabies biologics market in 2017.
    Vaccine. 2018 Nov 9. pii: S0264-410X(18)31364.
    >> Share

    October 2018
  47. O'BRIEN KL, Nolan T
    The WHO position on rabies immunization - 2018 updates.
    Vaccine. 2018 Oct 17. pii: S0264-410X(18)31366.
    >> Share

  48. LI AJ, Sreenivasan N, Siddiqi UR, Tahmina S, et al
    Descriptive assessment of rabies post-exposure prophylaxis procurement, distribution, monitoring, and reporting in four Asian countries: Bangladesh, Bhutan, Cambodia, and Sri Lanka, 2017-2018.
    Vaccine. 2018 Oct 9. pii: S0264-410X(18)31363.
    >> Share

  49. CHANGALUCHA J, Steenson R, Grieve E, Cleaveland S, et al
    The need to improve access to rabies post-exposure vaccines: Lessons from Tanzania.
    Vaccine. 2018 Oct 8. pii: S0264-410X(18)31243.
    >> Share

    August 2018
  50. FOOKS AR, Banyard AC, Ertl HCJ
    New human rabies vaccines in the pipeline.
    Vaccine. 2018 Aug 25. pii: S0264-410X(18)31168.
    >> Share

  51. GONGAL G, Sampath G
    Introduction of intradermal rabies vaccination - A paradigm shift in improving post-exposure prophylaxis in Asia.
    Vaccine. 2018 Aug 24. pii: S0264-410X(18)31163.
    >> Share

    Rabies vaccines: WHO position paper, April 2018 - Recommendations.
    Vaccine. 2018 Aug 11. pii: S0264-410X(18)30902.
    >> Share

  53. SHI W, Kou Y, Xiao J, Zhang L, et al
    Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants.
    Vaccine. 2018;36:5020-5029.
    >> Share

  54. GILBERT A, Johnson S, Walker N, Wickham C, et al
    Efficacy of Ontario Rabies Vaccine Baits (ONRAB) against rabies infection in raccoons.
    Vaccine. 2018;36.
    >> Share

    June 2018
  55. HOENIG LJ, Jackson AC, Dickinson GM
    The early use of Pasteur's rabies vaccine in the United States.
    Vaccine. 2018 Jun 16. pii: S0264-410X(18)30623.
    >> Share

    May 2018
  56. MARTINA BEE, Smreczak M, Orlowska A, Marzec A, et al
    Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus.
    Vaccine. 2018 May 26. pii: S0264-410X(18)30705.
    >> Share

  57. MAROSI A, Dufkova L, Forro B, Felde O, et al
    Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin.
    Vaccine. 2018 May 24. pii: S0264-410X(18)30706.
    >> Share

    April 2018
  58. KORAKA P, Martina BEE, Smreczak M, Orlowska A, et al
    Inhibition of caspase-1 prolongs survival of mice infected with rabies virus.
    Vaccine. 2018 Apr 10. pii: S0264-410X(18)30470.
    >> Share

  59. SMRECZAK M, Orlowska A, Marzec A, Trebas P, et al
    The effect of combined drugs therapy on the course of clinical rabies infection in a murine model.
    Vaccine. 2018 Apr 9. pii: S0264-410X(18)30471.
    >> Share

    March 2018
  60. CLEATON JM, Wallace RM, Crowdis K, Gibson A, et al
    Impact of community-delivered SMS alerts on dog-owner participation during a mass rabies vaccination campaign, Haiti 2017.
    Vaccine. 2018 Mar 23. pii: S0264-410X(18)30353.
    >> Share

  61. PHOOLCHAROEN W, Banyard AC, Prehaud C, Selden D, et al
    In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity.
    Vaccine. 2018 Mar 6. pii: S0264-410X(18)30244.
    >> Share

    February 2018
  62. MAROSI A, Forgach P, Gyuranecz M, Sulyok KM, et al
    Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication.
    Vaccine. 2018 Feb 16. pii: S0264-410X(18)30155.
    >> Share

  63. PFAFF F, Muller T, Freuling CM, Fehlner-Gardiner C, et al
    In-depth genome analyses of viruses from vaccine-derived rabies cases and corresponding live-attenuated oral rabies vaccines.
    Vaccine. 2018 Feb 10. pii: S0264-410X(18)30156.
    >> Share

    January 2018
  64. VOS A, Freuling C, Ortmann S, Kretzschmar A, et al
    An assessment of shedding with the oral rabies virus vaccine strain SPBN GASGAS in target and non-target species.
    Vaccine. 2018 Jan 8. pii: S0264-410X(17)31839.
    >> Share

    December 2017
  65. JOCHMANS D, Neyts J
    The path towards effective antivirals against rabies.
    Vaccine. 2017 Dec 23. pii: S0264-410X(17)31812.
    >> Share

  66. DUFKOVA L, Sirmarova J, Salat J, Honig V, et al
    Mannitol treatment is not effective in therapy of rabies virus infection in mice.
    Vaccine. 2017 Dec 20. pii: S0264-410X(17)31781.
    >> Share

    November 2017
  67. GALVEZ-ROMERO G, Salas-Rojas M, Pompa-Mera EN, Chavez-Rueda K, et al
    Addition of C3d-P28 adjuvant to a rabies DNA vaccine encoding the G5 linear epitope enhances the humoral immune response and confers protection.
    Vaccine. 2017 Nov 27. pii: S0264-410X(17)31611.
    >> Share

  68. SIRIKUN J, Suputtamongkol Y, Rattanachinakorn P, Primsirikunawut A, et al
    Immunogenic response in obese patients undergoing rabies post-exposure prophylaxis with combined equine rabies immunoglobulin and rabies vaccination.
    Vaccine. 2017 Nov 27. pii: S0264-410X(17)31622.
    >> Share

  69. KALIMUDDIN S, Wijaya L, Chan YFZ, Wong AWL, et al
    A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen.
    Vaccine. 2017 Nov 21. pii: S0264-410X(17)31526.
    >> Share

  70. SMRECZAK M, Marzec A, Orlowska A, Trebas P, et al
    The effect of selected molecules influencing the detrimental host immune response on a course of rabies virus infection in a murine model.
    Vaccine. 2017 Nov 15. pii: S0264-410X(17)31527.
    >> Share

  71. BAGHI HB, Bazmani A, Aghazadeh M
    Canine vaccination: Bridging the rabies knowledge gap.
    Vaccine. 2017 Nov 15. pii: S0264-410X(17)31575.
    >> Share

  72. BANYARD AC, Mansfield KL, Wu G, Selden D, et al
    Re-evaluating the effect of Favipiravir treatment on rabies virus infection.
    Vaccine. 2017 Nov 10. pii: S0264-410X(17)31541.
    >> Share

    October 2017
  73. WERA E, Mourits MCM, Hogeveen H
    Cost-effectiveness of mass dog rabies vaccination strategies to reduce human health burden in Flores Island, Indonesia.
    Vaccine. 2017 Oct 24. pii: S0264-410X(17)31374.
    >> Share

  74. LEGER A, De Nardi M, Simons R, Adkin A, et al
    Assessment of biosecurity and control measures to prevent incursion and to limit spread of emerging transboundary animal diseases in Europe: An expert survey.
    Vaccine. 2017;35:5956-5966.
    >> Share

  75. SMITH TG, Millien M, Vos A, Fracciterne FA, et al
    Evaluation of immune responses in dogs to oral rabies vaccine under field conditions.
    Vaccine. 2017 Oct 17. pii: S0264-410X(17)31388.
    >> Share

  76. FREULING CM, Eggerbauer E, Finke S, Kaiser C, et al
    Efficacy of the oral rabies virus vaccine strain SPBN GASGAS in foxes and raccoon dogs.
    Vaccine. 2017 Oct 14. pii: S0264-410X(17)31366.
    >> Share

    September 2017
  77. GIEL-MOLONEY M, Rumyantsev AA, David F, Figueiredo M, et al
    A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector.
    Vaccine. 2017 Sep 9. pii: S0264-410X(17)31153.
    >> Share

  78. NAKAGAWA K, Nakagawa K, Omatsu T, Katayama Y, et al
    Generation of a novel live rabies vaccine strain with a high level of safety by introducing attenuating mutations in the nucleoprotein and glycoprotein.
    Vaccine. 2017 Sep 4. pii: S0264-410X(17)31138.
    >> Share

    July 2017
  79. RECUENCO S, Warnock E, Osinubi MOV, Rupprecht CE, et al
    A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults.
    Vaccine. 2017 Jul 5. pii: S0264-410X(17)30880.
    >> Share

    June 2017
  80. VOS A, Freuling CM, Hundt B, Kaiser C, et al
    Oral vaccination of wildlife against rabies: Differences among host species in vaccine uptake efficiency.
    Vaccine. 2017 Jun 19. pii: S0264-410X(17)30799.
    >> Share

  81. KNOBEL DL, Arega S, Reininghaus B, Simpson GJG, et al
    Rabies vaccine is associated with decreased all-cause mortality in dogs.
    Vaccine. 2017 Jun 8. pii: S0264-410X(17)30765.
    >> Share

    March 2017
  82. VESCOVO P, Rettby N, Ramaniraka N, Liberman J, et al
    Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect.
    Vaccine. 2017;35:1782-1788.
    >> Share

  83. WILDE H, Ghai S, Hemachudha T
    Rabies: Still a silent killer targeting the poor.
    Vaccine. 2017 Mar 23. pii: S0264-410X(17)30294.
    >> Share

    February 2017
  84. LAVAN RP, King AI, Sutton DJ, Tunceli K, et al
    Rationale and support for a One Health program for canine vaccination as the most cost-effective means of controlling zoonotic rabies in endemic settings.
    Vaccine. 2017 Feb 16. pii: S0264-410X(17)30195.
    >> Share

    January 2017
  85. WIJAYA L, Tham CY, Chan YF, Wong AW, et al
    An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers.
    Vaccine. 2017 Jan 21. pii: S0264-410X(16)31256.
    >> Share

  86. LUO J, Zhang B, Wu Y, Tian Q, et al
    Expression of interleukin-6 by a recombinant rabies virus enhances its immunogenicity as a potential vaccine.
    Vaccine. 2017 Jan 12. pii: S0264-410X(17)30006.
    >> Share

  87. MORGEAUX S, Poirier B, Ragan CI, Wilkinson D, et al
    Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study.
    Vaccine. 2017 Jan 9. pii: S0264-410X(16)31264.
    >> Share

  88. GESSNER BD, Knobel DL, Conan A, Finn A, et al
    Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine?
    Vaccine. 2017 Jan 5. pii: S0264-410X(17)30001.
    >> Share

    November 2016
  89. MANSFIELD KL, Andrews N, Goharriz H, Goddard T, et al
    Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans.
    Vaccine. 2016;34:5959-5967.
    >> Share

    October 2016
  90. LANKESTER FJ, Wouters PA, Czupryna A, Palmer GH, et al
    Thermotolerance of an inactivated rabies vaccine for dogs.
    Vaccine. 2016 Oct 8. pii: S0264-410X(16)30913.
    >> Share

    September 2016
  91. STADING BR, Osorio JE, Velasco-Villa A, Smotherman M, et al
    Infectivity of attenuated poxvirus vaccine vectors and immunogenicity of a raccoonpox vectored rabies vaccine in the Brazilian Free-tailed bat (Tadarida brasiliensis).
    Vaccine. 2016 Sep 17. pii: S0264-410X(16)30796.
    >> Share

    August 2016
  92. VUTA V, Picard-Meyer E, Robardet E, Barboi G, et al
    Vaccine-induced rabies case in a cow (Bos taurus): Molecular characterisation of vaccine strain in brain tissue.
    Vaccine. 2016 Aug 27. pii: S0264-410X(16)30670.
    >> Share

  93. BOSE A, Munshi R, Tripathy RM, Madhusudana SN, et al
    A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes.
    Vaccine. 2016 Aug 20. pii: S0264-410X(16)30662.
    >> Share

  94. SILLERO-ZUBIRI C, Marino J, Gordon CH, Bedin E, et al
    Feasibility and efficacy of oral rabies vaccine SAG2 in endangered Ethiopian wolves.
    Vaccine. 2016 Aug 16. pii: S0264-410X(16)30693.
    >> Share

    July 2016
  95. LUO J, Shi H, Tan Y, Niu X, et al
    Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus.
    Vaccine. 2016 Jul 19. pii: S0264-410X(16)30603.
    >> Share

    May 2016
  96. KORIMBOCUS J, Dehay N, Tordo N, Cano F, et al
    Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use.
    Vaccine. 2016 May 3. pii: S0264-410X(16)30261.
    >> Share

    March 2016
  97. YENDO AC, de Costa F, Cibulski SP, Teixeira TF, et al
    A rabies vaccine adjuvanted with saponins from leaves of the soap tree (Quillaja brasiliensis) induces specific immune responses and protects against lethal challenge.
    Vaccine. 2016 Mar 28. pii: S0264-410X(16)30066.
    >> Share

    Every rabies death is a veterinary and health system failure until proven otherwise.
    Vaccine. 2016 Mar 21. pii: S0264-410X(16)30033.
    >> Share

  99. AGUEMON CT, Tarantola A, Zoumenou E, Goyet S, et al
    Rabies transmission risks during peripartum - Two cases and a review of the literature.
    Vaccine. 2016 Mar 3. pii: S0264-410X(16)00260.
    >> Share

    December 2015
  100. ABD-ELGHAFFAR AA, Ali AE, Boseila AA, Amin MA, et al
    Inactivation of rabies virus by hydrogen peroxide.
    Vaccine. 2015 Dec 27. pii: S0264-410X(15)01838.
    >> Share

    November 2015
  101. LECHENNE M, Oussiguere A, Naissengar K, Mindekem R, et al
    Operational performance and analysis of two rabies vaccination campaigns in N'Djamena, Chad.
    Vaccine. 2015 Nov 27. pii: S0264-410X(15)01675.
    >> Share

  102. WILDE H, Lumlertdacha B, Meslin FX, Ghai S, et al
    Worldwide rabies deaths prevention-A focus on the current inadequacies in postexposure prophylaxis of animal bite victims.
    Vaccine. 2015 Nov 25. pii: S0264-410X(15)01678.
    >> Share

  103. KOROU LM, Tasioudi KE, Tzani M, Konstantinidis A, et al
    Evaluation of the first oral rabies vaccination campaign of the red foxes in Greece.
    Vaccine. 2015 Nov 23. pii: S0264-410X(15)01673.
    >> Share

    July 2015
  104. SIGOILLOT-CLAUDE C, Battaglio M, Fiorucci M, Gillet D, et al
    A versatile in vitro ELISA test for quantification and quality testing of infectious, inactivated and formulated rabies virus used in veterinary monovalent or combination vaccine.
    Vaccine. 2015 Jul 2. pii: S0264-410X(15)00906.
    >> Share

    June 2015
  105. BANGA N, Guss P, Banga A, Rosenman KD, et al
    Reply to letter to the editor.
    Vaccine. 2015;33:2736.
    >> Share

    April 2015
  106. FONTANA D, Kratje R, Etcheverrigaray M, Prieto C, et al
    Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate.
    Vaccine. 2015 Apr 10. pii: S0264-410X(15)00418.
    >> Share

    March 2015
  107. SMITH TG, Siirin M, Wu X, Hanlon CA, et al
    Rabies vaccine preserved by vaporization is thermostable and immunogenic.
    Vaccine. 2015 Mar 23. pii: S0264-410X(15)00324.
    >> Share

  108. DUMAS FR, N'Diaye DS, Paireau J, Gautret P, et al
    Cost-effectiveness of rabies post-exposure prophylaxis in the context of very low rabies risk: A decision-tree model based on the experience of France.
    Vaccine. 2015 Mar 19. pii: S0264-410X(15)00286.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016